[educational] A non-peptide, oral small-molecule GLP-1 receptor agonist (FDA-approved). Easy to take (no food/water restrictions); 79% oral bioavailability vs semaglutide’s 1–2%. — Oral GLP-1 review
Mechanism & effects
[educational]Partial / biased agonism (avoids β-arrestin → less receptor desensitization); 11.2% weight loss (less than oral semaglutide 25 mg+). Cleared by CYP3A4 (drug interactions); raises heart rate most of the GLP-1s (+9 bpm). — Oral GLP-1 review
Cautions
[warning] Non-peptide → higher theoretical off-target/drug-interaction risk than the peptide GLP-1s; lacks their proven end-outcome (CVD/CKD/dementia) data so far.